News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,444 Results
Type
Article (42435)
Company Profile (270)
Press Release (686729)
Multimedia
Podcasts (90)
Webinars (17)
Section
Business (207175)
Career Advice (2143)
Deals (35969)
Drug Delivery (117)
Drug Development (81957)
Employer Resources (176)
FDA (16501)
Job Trends (15042)
News (350172)
Policy (33155)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2606)
Accelerated approval (32)
Adcomms (24)
Allergies (142)
Alliances (49930)
ALS (173)
Alzheimer's disease (1683)
Antibody-drug conjugate (ADC) (312)
Approvals (16760)
Artificial intelligence (520)
Autoimmune disease (157)
Automation (39)
Bankruptcy (367)
Best Places to Work (11692)
BIOSECURE Act (20)
Biosimilars (190)
Biotechnology (175)
Bladder cancer (158)
Brain cancer (56)
Breast cancer (640)
Cancer (4818)
Cardiovascular disease (398)
Career advice (1812)
Career pathing (37)
CAR-T (282)
CDC (46)
Celiac Disease (2)
Cell therapy (747)
Cervical cancer (36)
Clinical research (69959)
Collaboration (1707)
Company closure (4)
Compensation (1156)
Complete response letters (57)
COVID-19 (2750)
CRISPR (88)
C-suite (862)
Cystic fibrosis (143)
Data (6224)
Decentralized trials (2)
Denatured (27)
Depression (136)
Diabetes (501)
Diagnostics (6726)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (256)
Drug pricing (187)
Drug shortages (30)
Duchenne muscular dystrophy (237)
Earnings (91278)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (118322)
Executive appointments (995)
FDA (19618)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1477)
Gene editing (195)
Generative AI (43)
Gene therapy (603)
GLP-1 (982)
Government (4763)
Grass and pollen (6)
Guidances (383)
Healthcare (19056)
HIV (58)
Huntington's disease (44)
IgA nephropathy (82)
Immunology and inflammation (252)
Immuno-oncology (58)
Indications (110)
Infectious disease (3020)
Inflammatory bowel disease (190)
Inflation Reduction Act (14)
Influenza (117)
Intellectual property (250)
Interviews (337)
IPO (16785)
IRA (50)
Job creations (3686)
Job search strategy (1514)
JPM (58)
Kidney cancer (16)
Labor market (85)
Layoffs (554)
Leadership (32)
Legal (8075)
Liver cancer (91)
Longevity (15)
Lung cancer (647)
Lymphoma (375)
Machine learning (42)
Management (59)
Manufacturing (804)
MASH (165)
Medical device (13861)
Medtech (13916)
Mergers & acquisitions (20255)
Metabolic disorders (1274)
Multiple sclerosis (162)
NASH (16)
Neurodegenerative disease (321)
Neuropsychiatric disorders (90)
Neuroscience (2923)
Neurotech (1)
NextGen: Class of 2026 (6579)
Non-profit (4553)
Now hiring (67)
Obesity (599)
Opinion (269)
Ovarian cancer (166)
Pain (198)
Pancreatic cancer (231)
Parkinson's disease (283)
Partnered (33)
Patents (499)
Patient recruitment (489)
Peanut (56)
People (59833)
Pharmaceutical (64)
Pharmacy benefit managers (31)
Phase 1 (21812)
Phase 2 (30783)
Phase 3 (22949)
Pipeline (5282)
Policy (286)
Postmarket research (2608)
Preclinical (9257)
Press Release (66)
Prostate cancer (238)
Psychedelics (51)
Radiopharmaceuticals (286)
Rare diseases (841)
Real estate (6012)
Recruiting (72)
Regulatory (24718)
Reports (52)
Research institute (2417)
Resumes & cover letters (364)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (151)
Series A (241)
Series B (192)
Service/supplier (11)
Sickle cell disease (95)
Special edition (22)
Spinal muscular atrophy (159)
Sponsored (41)
Startups (3664)
State (2)
Stomach cancer (17)
Supply chain (105)
Tariffs (85)
The Weekly (61)
Vaccines (1020)
Venture capital (89)
Weight loss (384)
Women's health (92)
Worklife (18)
Date
Today (147)
Last 7 days (590)
Last 30 days (2113)
Last 365 days (30113)
2026 (3415)
2025 (30385)
2024 (35464)
2023 (40358)
2022 (51466)
2021 (55991)
2020 (54429)
2019 (46947)
2018 (35377)
2017 (32489)
2016 (31931)
2015 (37949)
2014 (31731)
2013 (26770)
2012 (29002)
2011 (29676)
2010 (27738)
Location
Africa (768)
Alabama (83)
Alaska (7)
Arizona (312)
Arkansas (14)
Asia (40041)
Australia (6567)
California (11325)
Canada (3292)
China (1110)
Colorado (484)
Connecticut (483)
Delaware (337)
Europe (86541)
Florida (1690)
Georgia (358)
Hawaii (3)
Idaho (61)
Illinois (864)
India (65)
Indiana (520)
Iowa (22)
Japan (431)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1382)
Massachusetts (8124)
Michigan (324)
Minnesota (629)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3023)
New Mexico (28)
New York (2986)
North Carolina (1468)
North Dakota (8)
Northern California (5530)
Ohio (336)
Oklahoma (21)
Oregon (41)
Pennsylvania (2278)
Puerto Rico (24)
Rhode Island (47)
South America (1136)
South Carolina (66)
South Dakota (1)
Southern California (4412)
Tennessee (174)
Texas (1740)
United States (40156)
Utah (336)
Vermont (1)
Virginia (260)
Washington D.C. (83)
Washington State (919)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
729,444 Results for "rapamycin holdings inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
December 16, 2025
·
7 min read
Press Releases
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies
December 15, 2025
·
13 min read
Press Releases
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
November 11, 2025
·
7 min read
Press Releases
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
September 24, 2025
·
7 min read
Press Releases
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
September 15, 2025
·
7 min read
Press Releases
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’s “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
October 24, 2025
·
6 min read
Press Releases
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
February 1, 2026
·
8 min read
Press Releases
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
February 10, 2026
·
18 min read
Press Releases
Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements
January 13, 2026
·
3 min read
Press Releases
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
October 14, 2025
·
7 min read
1 of 72,945
Next
